{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:17:11Z","timestamp":1790583431699,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-PCC-06-18"],"award-info":[{"award-number":["SU2C-AACR-PCC-06-18"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","award":["SU2C-AACR-PCC-06-18"],"award-info":[{"award-number":["SU2C-AACR-PCC-06-18"]}],"id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R50CA211556"],"award-info":[{"award-number":["R50CA211556"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11307-025-01989-3","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T18:51:46Z","timestamp":1740077506000},"page":"285-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of [18F]AlF NOTA-5G, an Aluminum [18F]fluoride Labeled Peptide Targeting the Cell Surface Receptor Integrin Alpha(v)beta(6) for PET Imaging"],"prefix":"10.1007","volume":"27","author":[{"given":"Sven H.","family":"Hausner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanushree","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-4082","authenticated-orcid":false,"given":"Julie L.","family":"Sutcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"1989_CR1","doi-asserted-by":"crossref","unstructured":"Davis RA, Ganguly T, Hausner SH, Sutcliffe JL. Peptides as vectors for radiopharmaceutical therapy. 2023:275\u2013295. In: Bodei L, Lewis JS, Zeglis BM (eds.), Radiopharmaceutical therapy, Springer, Cham, p 275\u2013295.","DOI":"10.1007\/978-3-031-39005-0_13"},{"key":"1989_CR2","doi-asserted-by":"crossref","unstructured":"Lewis JS, Windhorst AD, Zeglis BM (eds) (2019) Radiopharmaceutical chemistry. Springer, Cham","DOI":"10.1007\/978-3-319-98947-1"},{"key":"1989_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.canlet.2017.06.012","volume":"403","author":"J Niu","year":"2017","unstructured":"Niu J, Li Z (2017) The roles of integrin \u03b1v\u03b26 in cancer. Cancer Lett 403:128\u2013137","journal-title":"Cancer Lett"},{"issue":"5","key":"1989_CR4","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1158\/0008-5472.CAN-13-1796","volume":"74","author":"A Dutta","year":"2014","unstructured":"Dutta A, Li J, Lu H et al (2014) Integrin alpha(v)beta(6) promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Res 74(5):1598\u20131608","journal-title":"Cancer Res"},{"issue":"7","key":"1989_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2174\/138945009788680374","volume":"10","author":"A Bandyopadhyay","year":"2009","unstructured":"Bandyopadhyay A, Raghavan S (2009) Defining the role of integrin alpha(v)beta(6) in cancer. Curr Drug Targets 10(7):645\u2013652","journal-title":"Curr Drug Targets"},{"issue":"2","key":"1989_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40291-020-00450-1","volume":"24","author":"A Desnoyers","year":"2020","unstructured":"Desnoyers A, Gonzalez C, Perez-Segura P, Pandiella A, Amir E, Ocana A (2020) Integrin alpha v beta 6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis. Mol Diagn Ther 24(2):143\u2013151","journal-title":"Mol Diagn Ther"},{"issue":"6","key":"1989_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s11307-016-0959-4","volume":"18","author":"SWL de Geus","year":"2016","unstructured":"de Geus SWL, Boogerd LSF, Swijnenburg R-J et al (2016) Selecting tumor-specific molecular targets in pancreatic adenocarcinoma: Paving the way for image-guided pancreatic surgery. Mol Imaging Biol 18(6):807\u2013819","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"1989_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/path.5320","volume":"249","author":"CS Reader","year":"2019","unstructured":"Reader CS, Vallath S, Steele CW et al (2019) The integrin \u03b1v\u03b26 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. J Pathol 249(3):332\u2013342","journal-title":"J Pathol"},{"key":"1989_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2967\/jnumed.122.264749","volume":"64","author":"T Ganguly","year":"2023","unstructured":"Ganguly T, Bauer N, Davis RA et al (2023) Preclinical evaluation of 68Ga- and 177Lu-labeled integrin \u03b1v\u03b26-targeting radiotheranostic peptides. J Nucl Med 64:639\u2013644","journal-title":"J Nucl Med"},{"key":"1989_CR10","doi-asserted-by":"publisher","first-page":"108892","DOI":"10.1016\/j.nucmedbio.2024.108892","volume":"130\u2013131","author":"IE Wang","year":"2024","unstructured":"Wang IE, Brooks AF, Clark M, Morrissette LJ, Scott PJH (2024) Improved purification of cyclotron [68Ga]GaCl3 for the production of 68Ga radiopharmaceuticals. Nucl Med Biol 130\u2013131:108892","journal-title":"Nucl Med Biol"},{"issue":"3","key":"1989_CR11","first-page":"163","volume":"35","author":"K Kumar","year":"2020","unstructured":"Kumar K (2020) The current status of the production and supply of gallium-68. Cancer Biother Radiopharm 35(3):163\u2013166","journal-title":"Cancer Biother Radiopharm"},{"key":"1989_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","volume":"76","author":"A Sanchez-Crespo","year":"2013","unstructured":"Sanchez-Crespo A (2013) Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot 76:55\u201362","journal-title":"Appl Radiat Isot"},{"key":"1989_CR13","unstructured":"International Atomic Energy Agency (2021) Production and quality control of fluorine-18 labelled radiopharmaceuticals. IAEA-TECDOC-1968, IAEA, Vienna"},{"issue":"4","key":"1989_CR14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1021\/acs.bioconjchem.7b00817","volume":"29","author":"K Kumar","year":"2018","unstructured":"Kumar K, Ghosh A (2018) 18F-AlF labeled peptide and protein conjugates as positron emission tomography imaging pharmaceuticals. Bioconjugate Chem 29(4):953\u2013975","journal-title":"Bioconjugate Chem"},{"issue":"12","key":"1989_CR15","doi-asserted-by":"publisher","first-page":"20536","DOI":"10.3390\/molecules191220536","volume":"19","author":"S Richter","year":"2014","unstructured":"Richter S, Wuest F (2014) 18F-Labeled peptides: the future is bright. Molecules 19(12):20536\u201320556","journal-title":"Molecules"},{"issue":"4","key":"1989_CR16","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1039\/D2MD00397J","volume":"14","author":"M Failla","year":"2023","unstructured":"Failla M, Floresta G, Abbate V (2023) Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling. RSC Medicinal Chemistry 14(4):592\u2013623","journal-title":"RSC Medicinal Chemistry"},{"key":"1989_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41181-021-00141-0","volume":"6","author":"SJ Archibald","year":"2021","unstructured":"Archibald SJ, Allott L (2021) The aluminium-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules. EJNMMI Radiopharmacy and Chemistry 6:30","journal-title":"EJNMMI Radiopharmacy and Chemistry"},{"issue":"16","key":"1989_CR18","doi-asserted-by":"publisher","first-page":"7833","DOI":"10.1158\/0008-5472.CAN-07-1026","volume":"67","author":"SH Hausner","year":"2007","unstructured":"Hausner SH, DiCara D, Marik J, Marshall JF, Sutcliffe JL (2007) Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: Generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alpha(v)beta(6) expression with positron emission tomography. Cancer Res 67(16):7833\u20137840","journal-title":"Cancer Res"},{"issue":"14","key":"1989_CR19","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1158\/0008-5472.CAN-08-4410","volume":"69","author":"SH Hausner","year":"2009","unstructured":"Hausner SH, Abbey CK, Bold RJ et al (2009) Targeted in vivo imaging of integrin alpha(v)beta(6) with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res 69(14):5843\u20135850","journal-title":"Cancer Res"},{"key":"1989_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-3-319-98947-1_8","volume-title":"Radiopharmaceutical chemistry","author":"RA Davis","year":"2019","unstructured":"Davis RA, Hausner SH, Sutcliffe JL (2019) Peptides as radiopharmaceutical vectors. In: Lewis JS, Windhorst AD, Zeglis BM (eds) Radiopharmaceutical chemistry. Springer International Publishing, Cham, pp 137\u2013162"},{"issue":"1","key":"1989_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.nucmedbio.2013.09.009","volume":"41","author":"SH Hausner","year":"2014","unstructured":"Hausner SH, Bauer N, Sutcliffe JL (2014) In vitro and in vivo evaluation of the effects of aluminum [18F]fluoride radiolabeling on an integrin alpha(v)beta(6)-specific peptide. Nucl Med Biol 41(1):43\u201350","journal-title":"Nucl Med Biol"},{"key":"1989_CR22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s11307-020-01500-0","volume":"22","author":"SH Hausner","year":"2020","unstructured":"Hausner SH, Bauer N, Davis RA, Ganguly T, Tang SYC, Sutcliffe JL (2020) The effects of an albumin binding moiety on the targeting and pharmacokinetics of an integrin \u03b1v\u03b26-selective peptide labeled with aluminum [18F]fluoride. Mol Imaging Biol 22:1543\u20131552","journal-title":"Mol Imaging Biol"},{"issue":"2","key":"1989_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2310\/7290.2009.00015","volume":"8","author":"SH Hausner","year":"2009","unstructured":"Hausner SH, Kukis DL, Gagnon MKJ et al (2009) Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alpha(v)beta(6)-specific peptide. Mol Imaging 8(2):111\u2013121","journal-title":"Mol Imaging"},{"issue":"3","key":"1989_CR24","doi-asserted-by":"publisher","first-page":"153535002003031","DOI":"10.1162\/15353500200303133","volume":"2","author":"AM Loening","year":"2003","unstructured":"Loening AM, Gambhir SS (2003) AMIDE: A free software tool for multimodality medical image analysis. Mol Imaging 2(3):153535002003031","journal-title":"Mol Imaging"},{"issue":"1","key":"1989_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11307-017-1097-3","volume":"20","author":"JB White","year":"2017","unstructured":"White JB, Hu LY, Boucher DL, Sutcliffe JL (2017) ImmunoPET Imaging of \u03b1v\u03b26 Expression Using an Engineered Anti-\u03b1v\u03b26 Cys-diabody Site-Specifically Radiolabeled with Cu-64: Considerations for Optimal Imaging with Antibody Fragments. Mol Imaging Biol 20(1):103\u2013113","journal-title":"Mol Imaging Biol"},{"key":"1989_CR26","doi-asserted-by":"crossref","unstructured":"Sachindra S, Hellberg T, Exner S, et al. SPECT\/CT imaging, biodistribution and radiation dosimetry of a 177lu-dota-integrin \u03b1v\u03b26 cystine knot peptide in a pancreatic cancer xenograft model. Front Oncol. 2021;11.","DOI":"10.3389\/fonc.2021.684713"},{"key":"1989_CR27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clinimag.2019.04.006","volume":"56","author":"J Ivanidze","year":"2019","unstructured":"Ivanidze J, Roytman M, Sasson A et al (2019) Molecular imaging and therapy of somatostatin receptor positive tumors. Clin Imaging 56:146\u2013154","journal-title":"Clin Imaging"},{"issue":"5","key":"1989_CR28","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1021\/cr900325h","volume":"110","author":"TJ Wadas","year":"2010","unstructured":"Wadas TJ, Wong EH, Weisman GR, Anderson CJ (2010) Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease. Chem Rev 110(5):2858\u20132902","journal-title":"Chem Rev"},{"key":"1989_CR29","doi-asserted-by":"crossref","unstructured":"Morris O, Fairclough M, Grigg J, Prenant C, McMahon A. A review of approaches to 18F radiolabelling affinity peptides and proteins. J Labelled Compd Radiopharm. 2018, 1\u201320.","DOI":"10.1002\/jlcr.3634"},{"issue":"20","key":"1989_CR30","doi-asserted-by":"publisher","first-page":"6818","DOI":"10.3390\/molecules27206818","volume":"27","author":"JH Dam","year":"2022","unstructured":"Dam JH, Langkj\u00e6r N, Baun C, Olsen BB, Nielsen AY, Thisgaard H (2022) Preparation and evaluation of [18F]AlF-NOTA-NOC for PET imaging of neuroendocrine tumors: comparison to [68Ga]Ga-DOTA\/NOTA-NOC. Molecules 27(20):6818","journal-title":"Molecules"},{"issue":"13","key":"1989_CR31","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","volume":"47","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Cleeren F, Tshibangu T et al (2020) [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging 47(13):3033\u20133046","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"64","key":"1989_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.122.264563","volume":"2023","author":"E Pauwels","year":"2023","unstructured":"Pauwels E, Cleeren F, Tshibangu T et al (2023) 18F-AlF-NOTA-octreotide outperforms 68Ga-DOTA-TATE\/-NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. J Nucl Med 2023(64):632\u2013638","journal-title":"J Nucl Med"}],"updated-by":[{"DOI":"10.1007\/s11307-025-01995-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000}}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-01989-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-01989-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-01989-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T19:40:13Z","timestamp":1746733213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-01989-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1989"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-01989-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11307-025-01995-5","asserted-by":"object"}]},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11307-025-01995-5","URL":"https:\/\/doi.org\/10.1007\/s11307-025-01995-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. H. H. is a co-inventor of intellectual property related to [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. J. L. S. is founder and CEO of and holds ownership interest (including patents) in Luminance Biosciences, Inc., and is a co-inventor of intellectual property related to [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}